A novel promotor which contains an aniline derivative is introduced. By using the promotor alone, the time and temperature of the curing reaction of the vinyl ester resin can be controlled by the unique steric effect and electronic properties of the aniline derivative. A method for preparing the above promotor is also introduced.

Provided is a hydrogenation catalyst for an amide compound, containing hydroxyapatite and platinum and vanadium that are fixed on the hydroxyapatite, 15 to 80% of the surface of the platinum being covered with vanadium. The hydrogenation catalyst can promote a reduction reaction in which an amide compound is converted into an amine compound, can be used under mild conditions, and has such durability that the catalyst can be repeatedly used while retaining a high activity.

Provided is a hydrogenation catalyst for an amide compound, containing hydroxyapatite and platinum and vanadium that are fixed on the hydroxyapatite, 15 to 80% of the surface of the platinum being covered with vanadium. The hydrogenation catalyst can promote a reduction reaction in which an amide compound is converted into an amine compound, can be used under mild conditions, and has such durability that the catalyst can be repeatedly used while retaining a high activity.

The invention relates to novel methods for preparing N-methyl-p-toluidine for the use thereof as additive for aviation fuel, and to specific catalysts for these methods.

The invention relates to novel methods for preparing N-methyl-p-toluidine for the use thereof as additive for aviation fuel, and to specific catalysts for these methods.

Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.

Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells. Disclosed herein are novel anticancer compounds that inhibit basal glucose transport, resulting in tumor suppression and new methods for the study of glucose deprivation in animal cancer research.

It is an object of the present invention to provide a catalyst for a cross-coupling reaction in which an organometallic complex is sufficiently immobilized on a carrier and an object product can be easily obtained. The catalyst for a cross-coupling reaction of the present invention has a carrier part composed of a synthetic resin and an organometallic complex part immobilized on the carrier part by chemical bonding, and has a structure represented by formula (P1), wherein in (P1) R.sup.1, R.sup.2 may be the same or different, and is a substituent such as a hydrogen atom. R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9 may be the same or different and are substituents, such as a hydrogen. X represents a halogen atom, and R.sup.7 represents a substituent having 3 to 20 carbon atoms with a π bond. RS1 represents the main chain of the synthetic resin precursors having —CH.sub.2OH group at their end.

##STR00001##

It is an object of the present invention to provide a catalyst for a cross-coupling reaction in which an organometallic complex is sufficiently immobilized on a carrier and an object product can be easily obtained. The catalyst for a cross-coupling reaction of the present invention has a carrier part composed of a synthetic resin and an organometallic complex part immobilized on the carrier part by chemical bonding, and has a structure represented by formula (P1), wherein in (P1) R.sup.1, R.sup.2 may be the same or different, and is a substituent such as a hydrogen atom. R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9 may be the same or different and are substituents, such as a hydrogen. X represents a halogen atom, and R.sup.7 represents a substituent having 3 to 20 carbon atoms with a π bond. RS1 represents the main chain of the synthetic resin precursors having —CH.sub.2OH group at their end.

##STR00001##

The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.